Mycelex

Erythrasma, Tinea Pedis, Inflammation + 37 more

Treatment

20 Active Studies for Mycelex

What is Mycelex

Clotrimazole

The Generic name of this drug

Treatment Summary

Clotrimazole is a medication used to treat fungal infections. It belongs to a class of drugs called imidazole antifungals and is available as creams, pessaries, or slowly dissolving tablets. Clotrimazole is known for its minimal side effects and easy metabolism, making it a popular treatment for fungal infections such as vaginal yeast infections and athlete's foot. It has also been studied for potential use in treating other diseases such as sickle cell disease, malaria, and some types of cancer.

Mycelex

is the brand name

image of different drug pills on a surface

Mycelex Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Mycelex

Clotrimazole

1983

116

Effectiveness

How Mycelex Affects Patients

Clotrimazole is an antifungal medicine that works by disrupting the cell walls of fungi, preventing them from growing. Generally, lower concentrations of clotrimazole stop the fungi from multiplying, while higher concentrations can actually kill the fungi. In the past, clotrimazole was very effective, but now it is often not as successful due to an increase in resistance in certain patients.

How Mycelex works in the body

Clotrimazole is an antifungal drug that works by damaging the protective barrier of fungal cells. It does this by blocking the production of a substance called ergosterol, which is an important building block of fungal cell membranes. Without this barrier, the cell is unable to function properly and the growth of the fungus is stopped. Clotrimazole also blocks other calcium-related processes like calcium-dependent potassium channels and voltage-dependent calcium channels. This leads to other effects beyond just stopping fungal growth.

When to interrupt dosage

The prescribed dose of Mycelex is contingent upon the diagnosed state, including Vulvitis, Trichophytosis and Radiotherapy Side Effects. The measure of dosage is contingent upon the delivery system (e.g. Cream or Topical) as demonstrated in the table beneath.

Condition

Dosage

Administration

Inflammation

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Trichomonas Vaginitis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Vulvitis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Vaginitis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Balanitis candida

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Skin candida

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Genital candidiasis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Ringworm

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Tinea

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Cellulitis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

symptomatic Tinea Corporis caused by Trichophyton mentagrophytes, Trichophyton rubrum, Epidermophyton floccosum

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Tinea cruris

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Oropharyngeal Candidiasis

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Tinea

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Epidermophyton floccosum

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Candidiasis, Vulvovaginal

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Communicable Diseases

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Mixed Vaginal Infections

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Tinea Cruris

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Chemotherapy Effects

0.01 mg/mg, , 10.0 mg/mL, 0.02 mg/mg, 1.0 mg/mL, 10.0 mg, 0.05 mg/mg, 0.035 mg/mg, 0.042 mg/mg, 0.01 mL/mL, 4.0 mg/mL, 6.0 mg/mL, 0.00001 mg/mg, 1.0 %, 500.0 mg, 2.0 %, 10.0 %, 100.0 mg, 200.0 mg, 1.0 mg/mg, 1000.0 mg/mL, 10.0 mg/mg, 0.0001 mg/mg, 0.011 mg/mg, 0.000001 mg/mg, 0.01 mg/mL, 0.006 mg/mL, 100.0 mg/mg

, Topical, Cream, Cream - Topical, Lotion, Lotion - Topical, Vaginal, Cream - Vaginal, Liquid, Liquid - Topical, Oral, Lozenge, Lozenge - Oral, Aerosol, foam, Aerosol, foam - Topical, Ointment, Ointment - Topical, Kit, Aerosol, spray - Topical, Aerosol, spray, Oil, Oil - Topical, Powder, Powder - Topical, Spray, Spray - Topical, Gel, Gel - Topical, Solution, Solution - Topical, Tablet - Vaginal, Tablet, Oral; Topical; Vaginal, Capsule; Cream, Capsule; Cream - Oral; Topical; Vaginal, Cream - Topical; Vaginal, Topical; Vaginal, Suppository - Vaginal, Suppository, Cream; Suppository, Cream; Suppository - Topical; Vaginal, Oral; Topical, Lozenge - Oral; Topical, Capsule; Cream; Kit, Capsule; Cream; Kit - Oral; Topical, Troche, Troche - Oral, Capsule; Cream - Oral; Topical, Cream; Kit, Cream; Kit; Tablet, Cream; Kit; Tablet - Topical; Vaginal, Cream; Kit - Topical; Vaginal, Spray - Extracorporeal, Extracorporeal, Kit - Topical

Warnings

Mycelex Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Clotrimazole may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Clotrimazole may interact with Pulse Frequency

There are 20 known major drug interactions with Mycelex.

Common Mycelex Drug Interactions

Drug Name

Risk Level

Description

Capmatinib

Major

The serum concentration of Capmatinib can be decreased when it is combined with Clotrimazole.

Rimegepant

Major

The metabolism of Rimegepant can be increased when combined with Clotrimazole.

(R)-warfarin

Moderate

The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Clotrimazole.

(S)-Warfarin

Moderate

The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Clotrimazole.

4-hydroxycoumarin

Moderate

The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Clotrimazole.

Mycelex Toxicity & Overdose Risk

Clotrimazole is unlikely to cause an overdose as it is unlikely to be absorbed in large amounts through one application or by accident after being swallowed. There is no specific treatment for an overdose. Animal studies have not shown any effects of the drug on fertility, but it is not recommended to be used by pregnant or breastfeeding women unless advised by a doctor. Symptoms of overdose may include redness, stinging, blistering, swelling, itching, burning, and general skin irritation, as well as cramps.

image of a doctor in a lab doing drug, clinical research

Mycelex Novel Uses: Which Conditions Have a Clinical Trial Featuring Mycelex?

There are currently 293 active trials exploring the utility of Mycelex in providing relief for Atopic Dermatitis, Tinea Inguinalis and Balanitis Candida.

Condition

Clinical Trials

Trial Phases

Tinea Versicolor

0 Actively Recruiting

Balanitis candida

0 Actively Recruiting

Mixed Vaginal Infections

0 Actively Recruiting

Skin Diseases

0 Actively Recruiting

symptomatic Tinea Corporis caused by Trichophyton mentagrophytes, Trichophyton rubrum, Epidermophyton floccosum

0 Actively Recruiting

Tinea cruris

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Oropharyngeal Candidiasis

0 Actively Recruiting

Tinea cruris

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Epidermophyton floccosum

0 Actively Recruiting

Malassezia

0 Actively Recruiting

Inflammation

58 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4

Cellulitis

0 Actively Recruiting

Steroids

0 Actively Recruiting

Radiotherapy Side Effects

2 Actively Recruiting

Phase 2, Not Applicable

Candidiasis, Vulvovaginal

0 Actively Recruiting

Tinea Pedis

0 Actively Recruiting

Mycelex Reviews: What are patients saying about Mycelex?

5

Patient Review

2/1/2010

Mycelex for Treatment to Prevent Candidiasis of Oropharynx

After initially seeing some success, I experienced a setback after forgetting to take the medication as directed. I'm now on my second bottle and still struggling. The side effects are incredibly uncomfortable, especially for someone with Crohn's like me.

4.7

Patient Review

9/7/2008

Mycelex for Thrush

4.3

Patient Review

2/12/2010

Mycelex for Thrush

I've been really pleased with this medication. I had four surgeries in five weeks, and the last one was due to a bone infection. I was put on IV antibiotics for six weeks, and I usually have a problem with oral antibiotics causing yeast infections and thrush. But I've had no signs of a flare up with Mycelex. They don't taste bad, either, which is a plus.

4

Patient Review

4/18/2011

Mycelex for Candidiasis Fungal Infection of the Oropharynx

Mycelex was effective after seven days, but I had to stop taking it due to severe allergic reactions. These included headaches, dizziness, and difficulty swallowing food.

3.7

Patient Review

6/18/2009

Mycelex for Thrush

My doctor prescribed this to me for the mouth sores caused by my chemotherapy. It's really easy to use, and I like that there is no taste.

3.7

Patient Review

11/11/2009

Mycelex for Thrush

I've been having stomach issues ever since I started taking this medication.

3.3

Patient Review

1/20/2011

Mycelex for Thrush

I'm only on day three of the Mycelex treatment, but I haven't seen much improvement yet. Hoping the full two weeks will make a big difference.

3

Patient Review

3/15/2010

Mycelex for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

2

Patient Review

6/25/2018

Mycelex for Thrush

I'm on my third bottle, and I still haven't seen a full recovery. Not sure what the next step is, but I hope to find something that works soon.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mycelex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you get mycelex over-the-counter?

"Mycelex Clotrimazole topical preparations are used to treat fungus infections on the skin. This medicine is available both over-the-counter (OTC) and with a prescription from your doctor."

Answered by AI

How long does it take for mycelex to work?

"Below are some frequently asked questions about clotrimazole lozenge:

How long does it take for clotrimazole to work?

Clotrimazole is absorbed by the body and begins to treat oral thrush within 30 to 60 minutes after taking your dose. Most people will begin to feel relief in about a week, but it takes 2 weeks to completely get rid of the fungus causing your infection."

Answered by AI

What is mycelex used for?

"Mycelex is a prescription medicine used to treat the symptoms of tinea pedis (Athlete's foot), tinea cruris (Jock itch), tinea corporis (Ringworm), vaginal candidiasis and superficial dermatologic infection. Mycelex may be used alone or with other medications."

Answered by AI

What are the side effects of mycelex?

"The side effects of the medication may include nausea, vomiting, mild itching, or an unpleasant sensation in the mouth."

Answered by AI

Clinical Trials for Mycelex

Image of ALS Global in Irving, United States.

GX-03 for Eczema

18 - 70
All Sexes
Irving, TX

This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), and the Peak Pruritus Numeric Rating Scale (PP-NRS). Safety will be evaluated through monitoring of treatment-emergent adverse events throughout the study period.

Phase 2
Recruiting

ALS Global

Turn Therapeutics

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of Seeding Labs INC in Austin, United States.

Tailored Recommendations for Infant Gut Microbiome

No minimum age - 3
All Sexes
Austin, TX

The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.

Waitlist Available
Has No Placebo

Seeding Labs INC

Qian Yuan, MD

Seeding, Inc DBA Tiny Health

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Mycelex clinical trials?

We made a collection of clinical trials featuring Mycelex, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT

The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)

Waitlist Available
Has No Placebo

UConn Health

Cutter Lindbergh, Ph.D.

Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT

The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.

Recruiting
Paid Trial

Department of Nutritional Sciences

Have you considered Mycelex clinical trials?

We made a collection of clinical trials featuring Mycelex, we think they might fit your search criteria.
Go to Trials
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Phase 2
Recruiting

Abcentra Investigational Site (+6 Sites)

Abcentra

Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN

Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.

Recruiting
Has No Placebo

School of Public Health

Have you considered Mycelex clinical trials?

We made a collection of clinical trials featuring Mycelex, we think they might fit your search criteria.
Go to Trials